NCT02819518View on ClinicalTrials.gov

Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355)

PHASE3CompletedINTERVENTIONAL

Enrollment

882

Participants

Timeline

Start Date

July 27, 2016

Primary Completion Date

June 15, 2021

Study Completion Date

October 30, 2023

Conditions

Triple Negative Breast Cancer (TNBC)

Interventions

BIOLOGICAL

Pembrolizumab

IV infusion

DRUG

Nab-paclitaxel

IV infusion

DRUG

Paclitaxel

IV infusion

DRUG

Gemcitabine

IV infusion

DRUG

Carboplatin

IV infusion

DRUG

Normale Saline Solution

IV infusion

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02819518 - Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355) | Biotech Hunter | Biotech Hunter